PR Public relations news

• ROSEN, A LEADING LAW FIRM Encourages TuSimple Holdings, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action Commenced by the Firm - TSP

  11-12-2022 23:45
  
  NEW YORK, Dec. 11, 2022 /PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of TuSimple Holdings, Inc. (NASDAQ: TSP): (i) pursuant and/or traceable to the Registration Statement and Prospectus (collectively, the "Registration...
  
  Read more

• Blueprint Medicines Reports Clinical Data Highlighting Leadership in Developing Targeted Treatment Options for Patients with Systemic Mastocytosis

  11-12-2022 23:30
  
  -- 95 percent confirmed overall response rate and 37 percent confirmed complete remission rate in treatment-naïve patients with SM-AHN, the most common subtype of advanced SM, in PATHFINDER trial of AYVAKIT® (avapritinib) -- -- Ongoing survival benefits, with up to six years of follow-up,...
  
  Read more

• AbbVie Presents Data at the 64th American Society of Hematology (ASH) Annual Meeting Evaluating Epcoritamab (DuoBody®-CD3xCD20) Across B-Cell Lymphomas

  11-12-2022 23:30
  Four oral presentations presented at ASH highlight data evaluating investigational epcoritamab for the treatment of relapsed/refractory (R/R) follicular lymphoma, previously untreated follicular lymphoma, R/R diffuse large B-cell lymphoma and Richter's syndrome NORTH CHICAGO, Ill., Dec....
  
  Read more

• Boston Scientific Announces Strategic Investment to Acquire Majority Stake of Acotec Scientific Holdings Limited

  11-12-2022 23:17
  MARLBOROUGH, Mass., Dec. 11, 2022 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) and Acotec Scientific Holdings Limited ("Acotec" and 6669.HK) announced today that Boston Scientific will make a partial offer to acquire a majority stake, up to a maximum of 65%, of shares of...
  
  Read more

• Advertisement

• Splashdown! NASA's Orion Returns to Earth After Historic Moon Mission

  11-12-2022 21:47
  
  WASHINGTON, Dec. 11, 2022 /PRNewswire/ -- NASA's Orion spacecraft splashed down in the Pacific Ocean, west of Baja California, at 9:40 a.m. PST Sunday after a record-breaking mission, traveling more than 1.4 million miles on a path around the Moon and returning safely to Earth, completing...
  
  Read more

• Live from ASH 2022 | Ascentage Pharma Delivers Oral Presentations on Chinese Studies of Olverembatinib (HQP1351) at the ASH Annual Meeting for the Fifth Year, with Data Further Validating the Drug's Long-Term Efficacy and Safety

  11-12-2022 20:04
  
  SUZHOU, China and ROCKVILLE, Md., Dec. 11, 2022 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancers, chronic hepatitis B (CHB), and age-related diseases, today announced that it has delivered two Oral...
  
  Read more

• Jacobs Supports Successful Completion of NASA's Artemis I Moon Mission

  11-12-2022 19:44
  
  Jacobs' critical solutions and technologies help bring Orion home safely DALLAS, Dec. 11, 2022 /PRNewswire/ -- Jacobs (NYSE:J) congratulates NASA on the successful completion of the 25.5-day Artemis I mission to orbit the moon, following the safe splashdown of the Orion spacecraft in the...
  
  Read more

• Jackson State University graduates belong in every room, says commencement keynote Roland Martin

  11-12-2022 19:39
  
  JACKSON, Miss., Dec. 11, 2022 /PRNewswire/ -- Jackson State University's Fall 2022 commencement was a celebration of the ultimate academic milestone for the more than 500 graduates inside Lee E. Williams Athletic & Assembly Center on Friday, Dec. 9, 2022. The keynote speaker was...
  
  Read more

• Advertisement

• ROSEN, A LEADING LAW FIRM, Encourages Singularity Future Technology Ltd. f/k/a Sino-Global Shipping America Ltd. Investors to Secure Counsel Before Important Deadline in First Filed Securities Class Action Initiated by the Firm - SGLY

  11-12-2022 17:56
  
  NEW YORK, Dec. 11, 2022 /PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, announces it has filed a class action lawsuit on behalf of purchasers of the securities of Singularity Future Technology Ltd. f/k/a Sino-Global Shipping America Ltd. (NASDAQ: SGLY) between...
  
  Read more

• Coagulant Therapeutics Presents Data on an Exosite-Specific Nanobody Library to Activated Protein C (APC) at the 2022 American Society of Hematology (ASH) Annual Meeting

  11-12-2022 17:45
  
  Oral presentation describes a unique APC nanobody library and its potential as a source for novel treatments to diseases including trauma, hemophilia, ischemia and sepsis. SAN FRANCISCO, Dec. 11, 2022 /PRNewswire/ -- Coagulant Therapeutics Corporation, a privately held company focused on...
  
  Read more

• Poseida Therapeutics Presents Preclinical Data from P-FVIII-101 Gene Therapy for Hemophilia A at the 64th ASH Annual Meeting & Exposition

  11-12-2022 16:30
  
  Data demonstrate that a non-viral, liver-directed gene therapy utilizing Super piggyBac® (SPB) DNA Modification System achieved and maintained normalized human FVIII (hFVIII) activity following a single dose Data establishes preclinical proof of principle for treatment of Hemophilia A...
  
  Read more

• Pivotal Odronextamab (CD20xCD3) Phase 2 Data in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma Debut at ASH

  11-12-2022 16:30
  49% objective response rate (ORR) in heavily pre-treated patients who were naïve to prior CAR-T, with 31% achieving a complete response (CR) Even in patients who received prior CAR-T, 48% ORR and 32% CR observed in a dose expansion cohort from a Phase 1 trial Data will form the basis of...
  
  Read more

• Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In GrafTech To Contact Him Directly To Discuss Their Options

  11-12-2022 14:44
  
  NEW YORK, Dec. 11, 2022 /PRNewswire/ -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against GrafTech International Ltd. ("GrafTech" or the "Company") (NYSE: EAF). If you suffered losses exceeding $50,000 investing in GrafTech stock or...
  
  Read more

• Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Avaya To Contact Him Directly To Discuss Their Options

  11-12-2022 14:33
  
  NEW YORK, Dec. 11, 2022 /PRNewswire/ -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Avaya Holdings Corp. ("Avaya" or the "Company") (NYSE: AVYA). If you suffered losses exceeding $50,000 investing in Avaya stock or options and...
  
  Read more

• At COP15, Investors Announce Nature Action 100 to Tackle Nature Loss and Biodiversity Decline

  11-12-2022 14:32
  Participating investors will focus on mobilizing companies deemed to be systemically important to the goal of reversing nature and biodiversity loss by 2030; the initiative is encouraging investor signatories to participate ahead of its spring 2023 formal launch MONTREAL, Dec. 11, 2022...
  
  Read more

• Le jeu de combat en 2D « MELTY BLOOD: TYPE LUMINA » présente de nouveaux personnages gratuits, « Ushiwakamaru » et « Comte de Monte-Cristo », et annonce l'ajout de l'espagnol, du français et du portugais b

  11-12-2022 14:00
  
  TOKYO, 11 décembre 2022 /PRNewswire/ -- Project LUMINA (NotesCo., Ltd., Aniplex Inc., Lasengle Inc.) a annoncé le lancement des nouveaux personnages « Ushiwakamaru » et « Comte de Monte-Cristo » pour le jeu de combat 2D « MELTY BLOOD: TYPE LUMINA » disponible dans une mise à jour gratuite...
  
  Read more

• Jogo 2D de luta "MELTY BLOOD: TYPE LUMINA" anunciando novos personagens jogáveis gratuitos "Ushiwakamaru" e "Conde de Monte Cristo" e a nova adição de idiomas em espanhol, francês e português brasileiro

  11-12-2022 14:00
  
  TÓQUIO, 11 de dezembro de 2022 /PRNewswire/ -- o Project LUMINA (NotesCo., Ltd., Aniplex Inc., Lasengle Inc.) anuncia novos personagens jogáveis, "Ushiwakamaru" e "Conde de Monte Cristo", para o jogo de luta 2D "MELTY BLOOD: TYPE LUMINA" disponível em uma atualização gratuita no dia 15 de...
  
  Read more

• El juego de lucha 2D "MELTY BLOOD: TYPE LUMINA" anuncia nuevos personajes jugables gratuitos

  11-12-2022 14:00
  
  - El juego de lucha 2D "MELTY BLOOD: TYPE LUMINA" anuncia nuevos personajes jugables gratuitos "Ushiwakamaru" y "Conde de Montecristo" y la nueva incorporación de los idiomas español, francés y portugués brasileño TOKIO, 11 de diciembre de 2022 /PRNewswire/ -- Project LUMINA (NotesCo.,...
  
  Read more

• 2D-Kampfspiel „MELTY BLOOD: TYPE LUMINA" kündigt neue frei spielbare Charaktere wie „Ushiwakamaru" und „The Count of Monte Cristo" sowie die neuen Sprachversionen Spanisch, Französisch und Brasilianisches Portugiesisch an

  11-12-2022 14:00
  
  TOKIO, 11. Dezember 2022 /PRNewswire/ -- Project LUMINA (NotesCo., Ltd., Aniplex Inc., Lasengle Inc.) kündigt neue spielbare Charaktere, „Ushiwakamaru" und „The Count of Monte Cristo", für das 2D-Kampfspiel „MELTY BLOOD: TYPE LUMINA" an, das am 15. Dezember 2022*1 um 05:00 Uhr (UTC) in...
  
  Read more

• 2D Fighting Game "MELTY BLOOD: TYPE LUMINA" Announcing New Free Playable Characters "Ushiwakamaru" and "The Count of Monte Cristo" and the new addition of Spanish, French, and Brazilian Portuguese languages

  11-12-2022 14:00
  
  TOKYO, Dec. 11, 2022 /PRNewswire/ -- Project LUMINA (NotesCo., Ltd., Aniplex Inc., Lasengle Inc.) announces new playable characters, "Ushiwakamaru" and "The Count of Monte Cristo", for the 2D Fighting Game "MELTY BLOOD: TYPE LUMINA" available in a free update on December 15 at 5:00(UTC),...
  
  Read more

• UniTrust Venture Now Extends More Flexible Account Options Than Ever

  11-12-2022 13:58
  TALLINN, Estonia, Dec. 11, 2022 /PRNewswire/ -- Considering the expanding adoption of financial trading, the diversity at the hands of traders has also leveled up. Some participants are beginners, while others are professionals with many years of experience, so accordingly their trading...
  
  Read more

• PARTNER COMMUNICATIONS REPORTS THAT THE MINISTRY OF COMMUNICATIONS HAS PUBLISHED A FREQUENCIES TENDER

  11-12-2022 13:05
  
  ROSH HA'AYIN, Israel, Dec. 11, 2022 /PRNewswire/ -- Partner Communications Company Ltd. ("Partner" or the "Company") (NASDAQ: PTNR) (TASE: PTNR), a leading Israeli communications operator, reports that on December 7, 2022, the Israeli Ministry of Communications published the 5G tender...
  
  Read more

• Global Times: Historic summits chart course for China-Arab, GCC ties

  11-12-2022 10:53
  BEIJING, Dec. 11, 2022 /PRNewswire/ -- Chinese President Xi Jinping and leaders from Arab states and GCC countries on Friday gathered in Riyadh, capital of Saudi Arabia, to continue developing bilateral friendliness, chart the course for building a China-Arab community with a shared...
  
  Read more

• China recalibrates its COVID-19 response strategy

  11-12-2022 10:14
  
  BEIJING, Dec. 11, 2022 /PRNewswire/ -- After months of lining up every two to three days to take a nucleic acid test at temporary testing stations dotting the urban landscape, many Chinese residents were pleasantly surprised to learn on December 7 that they would no longer be required to...
  
  Read more

• XT.COM Lists MLXC in Its Innovation Zone

  11-12-2022 08:57
  SINGAPORE, Dec. 11, 2022 /PRNewswire/ -- XT.COM, the world's first socially infused trading platform, is thrilled to announce the listing of MLXC on its platform in the Innovation Zone and the MLXC/USDT trading pair will be open for trading from 2022-12-10 12:00 (UTC). Users can deposit...
  
  Read more

• Innovent Presents Phase 1b Clinical Data of IBI188 (Anti-CD47 Monoclonal Antibody) at the 2022 American Society of Hematology Annual Meeting

  11-12-2022 01:00
  ROCKVILLE, Md. and SUZHOU, China, Dec. 10, 2022 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, autoimmune, metabolic,...
  
  Read more

• Gracell Biotechnologies Presents Clinical Data for FasTCAR-T GC012F for High Risk, Newly Diagnosed Multiple Myeloma Demonstrating 100% Overall Response Rate

  11-12-2022 00:15
  
  BCMA/CD19 dual-targeting FasTCAR-T GC012F data from ongoing clinical trial presented at 64th American Society of Hematology Annual Meeting and Exposition SAN DIEGO and SUZHOU and SHANGHAI, China, Dec. 10, 2022 /PRNewswire/ -- Gracell Biotechnologies Inc. ("Gracell" or the "Company",...
  
  Read more

Follow @PR_UKnws on Twitter!